SomaLogic, Inc. (SLGC) |
|
2.36 0.02 (0.85%)
|
09-27 10:36 |
|
Open: |
2.34 |
Pre. Close: |
2.34 |
|
High:
|
2.38 |
Low:
|
2.245 |
|
Volume:
|
195,901 |
Market Cap:
|
444(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:19:22 AM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.8 One year: 3.27 |
| Support: |
Support1: 2.13 Support2: 1.97 |
| Resistance: |
Resistance1: 2.4 Resistance2: 2.8 |
| Pivot: |
2.27  |
| Moving Average: |
MA(5): 2.31 MA(20): 2.25
MA(100): 2.43 MA(250): 2.67 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 83.6 %D(3): 78.3 |
| RSI: |
RSI(14): 61.5 |
| 52-week: |
High: 3.78 Low: 1.92 |
| Average Vol(K): |
3-Month: 903 (K) 10-Days: 808 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SLGC ] has closed below upper band by 17.2%. Bollinger Bands are 54.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.38 - 2.4 |
2.4 - 2.41 |
|
Low:
|
2.24 - 2.25 |
2.25 - 2.27 |
|
Close:
|
2.32 - 2.34 |
2.34 - 2.36 |
|
Company Description |
|
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado. |
Headline News |
Tue, 26 Sep 2023
SomaLogic (NASDAQ:SLGC) Lowered to “Hold” at Canaccord ... - Defense World
Mon, 25 Sep 2023
Should You Buy Somalogic Inc (SLGC) Stock on Monday? - InvestorsObserver
Mon, 25 Sep 2023
The Unpredictable Downgrade of SomaLogic A Closer Look at ... - Best Stocks
Tue, 19 Sep 2023
SomaLogics Strategic Partnerships and the Future of Proteomics - Best Stocks
Sat, 16 Sep 2023
ARK Investment Management LLC Buys 1080616 Shares of ... - MarketBeat
Tue, 05 Sep 2023
SomaLogic expands agreement with Novo Nordisk to 2025 - SomaLogic (NASDAQ:SLGC) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Health Information Services |
| Shares Out. |
188 (M) |
| Shares Float |
154 (M) |
|
% Held by Insiders
|
8.9 (%) |
|
% Held by Institutions
|
69.1 (%) |
|
Shares Short
|
10,110 (K) |
|
Shares Short P.Month
|
9,590 (K) |
Stock Financials |
|
EPS
|
-0.75 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.74 |
|
Profit Margin (%)
|
-139.3 |
|
Operating Margin (%)
|
-153.9 |
|
Return on Assets (ttm)
|
-15.4 |
|
Return on Equity (ttm)
|
-25.2 |
|
Qtrly Rev. Growth
|
44.7 |
|
Gross Profit (p.s.)
|
-0.06 |
|
Sales Per Share
|
0.53 |
|
EBITDA (p.s.)
|
-0.8 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-134 (M) |
|
Levered Free Cash Flow
|
-66 (M) |
Stock Valuations |
|
PE Ratio
|
-3.14 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.85 |
|
Price to Sales
|
4.35 |
|
Price to Cash Flow
|
-3.31 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
